Cancer Institute of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China.
Mol Med Rep. 2018 Feb;17(2):2083-2088. doi: 10.3892/mmr.2017.8129. Epub 2017 Nov 22.
The immune system serves an important role in controlling and eradicating malignant cells. Immunotherapy for treating tumors has received much attention in recent years due to its marked effect. There are two approaches which currently lead this field: Chimeric antigen receptor‑modified T‑cell immunotherapy (CAR‑T) and programmed cell death protein-1 blockade (PD‑1 blockade). CAR‑T has emerged as a promising regimen for the treatment of a range of types of cancer, including chronic lymphoid leukemia and neuroblastoma, with studies of long term remission in certain patients. PD‑1 blockade has been reported to exert marked clinical responses in patients against a range of types of solid cancer, including advanced melanoma, non‑small‑cell lung cancer and renal cell carcinoma, in addition to hematological malignancies. While increasing the power of the immune system to fight cancer has been a long‑standing goal in oncology, a number of studies have demonstrated the synergistic antitumor effects of combination therapies under the umbrella of immunotherapy. The present review focused on a novel combination approach involving CAR‑T and PD‑1 blockade. The present reviews aimed to discuss the following four aspects of such an approach: i) Current monotherapy status; ii) rationale for the combination of CAR‑T and PD‑1 blockade; iii) current status of the combination of CAR‑T and PD‑1 blockade; and iv) conclusions and future perspectives.
免疫系统在控制和消灭恶性细胞方面起着重要作用。近年来，免疫疗法因其显著的疗效而受到广泛关注，用于治疗肿瘤。目前有两种方法引领着这一领域：嵌合抗原受体修饰 T 细胞免疫疗法（CAR-T）和程序性细胞死亡蛋白-1 阻断（PD-1 阻断）。CAR-T 已成为治疗多种癌症的一种很有前途的治疗方案，包括慢性淋巴细胞白血病和神经母细胞瘤，某些患者的长期缓解率研究已经证实了这一点。PD-1 阻断已被报道在多种实体瘤患者中发挥显著的临床反应，包括晚期黑色素瘤、非小细胞肺癌和肾细胞癌，以及血液恶性肿瘤。虽然增强免疫系统对抗癌症的能力一直是肿瘤学的一个长期目标，但许多研究已经证明了免疫疗法伞下联合治疗的协同抗肿瘤作用。本综述重点关注一种涉及 CAR-T 和 PD-1 阻断的新型联合方法。本综述旨在讨论这种方法的以下四个方面：i）目前的单药治疗现状；ii）CAR-T 和 PD-1 阻断联合的原理；iii）CAR-T 和 PD-1 阻断联合的现状；iv）结论和未来展望。
